KatherineFuhMDPhD

Gynecologic Oncology

Washington University, Gynecologic Oncology

Dr. Fuh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1825 4th St
Fl 6
San Francisco, CA 94143
Phone+1 415-353-9600

Fax+1 415-353-7657

Stanford Health Care-Sponsored Stanford UniversityFellowship, Gynecologic Oncology, 2009 - 2012
Stanford Health Care-Sponsored Stanford UniversityResidency, Obstetrics and Gynecology, 2005 - 2009
Georgetown University School of MedicineClass of 2005

PubMed

2 citations
Tumour evolution and microenvironment interactions in 2D and 3D space.
Chia-Kuei Mo, Jingxian Liu, Siqi Chen, Erik Storrs, Andre Luiz N Targino da Costa
Nature. 2024-10-01
260 citations
Proteogenomic Characterization of Endometrial Carcinoma.
Yongchao Dou, Emily Kawaler, Daniel Cui Zhou, Marina A. Gritsenko, Chen Huang
Cell. 2020-02-20
24 citations
Epigenetic regulation during cancer transitions across 11 tumour types.
Nadezhda V Terekhanova, Alla Karpova, Wen-Wei Liang, Alexander Strzalkowski, Siqi Chen
Nature. 2023-11-01

Journal Articles

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
Ian S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer
Ian S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research

Lectures

Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer.
2019 ASCO Annual Meeting - 6/1/2019

Aravive to Host Virtual KOL Event on Its Late-Stage Oncology Asset BatiraxceptMay 8th, 2023
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian CancerJanuary 4th, 2023
Gynecologic Cancer Clinicians and Researchers Recognized at SGO 2022 Annual Meeting on Women’s CancerMarch 21st, 2022
Join now to see all